Results 311 to 320 of about 22,609,350 (346)

Microbiota-dependent activation of CD4+ T cells induces CTLA-4 blockade–associated colitis via Fcγ receptors

Science
Immune checkpoint inhibitors can stimulate antitumor immunity but can also induce toxicities termed immune-related adverse events (irAEs). Colitis is a common and severe irAE that can lead to treatment discontinuation.
Bernard C. Lo, Ilona Kryczek, Jiali Yu, Linda Vatan, Roberta Caruso, M. Matsumoto, Yosuke Sato, Michael H. Shaw, N. Inohara, Yuying Xie, Y. Lei, Weiping Zou, Gabriel Núñez   +12 more
semanticscholar   +1 more source

CTLA-4 expressing ILC3s restrain interleukin-23 mediated inflammation

Nature
Interleukin (IL-)23 is a major mediator and therapeutic target in chronic inflammatory diseases that also elicits tissue protection in the intestine at homeostasis or following acute infection1–4.
Anees Ahmed, A. Joseph, Jordan Zhou, Veronika Horn, Jazib Uddin, Mengze Lyu, J. Goc, David Randy Gregory F. Ellen Robbyn Dana Vinita Laura Mi Artis Longman Sonnenberg Scherl Sockolow Lukin Jac, David Artis, Randy Longman, Gregory F. Sonnenberg, Ellen Scherl, R. Sockolow, Dana Lukin, Vinita E. Jacob, Laura Sahyoun, Michael Mintz, L. Gogokhia, Thomas Ciecierega, Aliza Solomon, Arielle Bergman, Kimberley Chein, Elliott Gordon, M. Ramos, Victoria Ribeiro de Godoy, Adriana Brcic-Susak, Seun Oguntunmibi, Dario Garone, Caitlin Mason, R. Sockolow, J. Wing, E. Vivier, S. Sakaguchi, Gregory F. Sonnenberg   +33 more
semanticscholar   +1 more source

CTLA-4 and Tolerance: The Biochemical Point of View

Immunologic Research, 2003
Potentially autoreactive T cells that escape negative selection in the thymus must be strictly controlled in the periphery to avoid autoimmune disease. The most robust regulatory process controlling autoreactivity is mediated by the CTLA-4-B7 pathway.
Shunsuke, Chikuma, Jeffrey A, Bluestone
openaire   +2 more sources

T-cell regulation by CD28 and CTLA-4

Nature Reviews Immunology, 2001
Activation of T lymphocytes is thought to require at least two signals, one delivered by the T-cell receptor complex after antigen recognition, and one provided on engagement of co-stimulatory receptors, such as CD28. Recent studies are providing clues as to the specific signalling roles of co-stimulatory receptors.
M L, Alegre, K A, Frauwirth, C B, Thompson   +2 more
openaire   +2 more sources

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Science, 1996
D. Leach, M. Krummel, J. Allison
semanticscholar   +1 more source

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

Science, 2008
K. Wing, Yasush Onishi, P. Prieto-Martin, Tomoyuki Yamaguchi, M. Miyara, Z. Fehérvári, T. Nomura, S. Sakaguchi   +7 more
semanticscholar   +1 more source

CTLA-4: Acting at the Synapse

Molecular Interventions, 2002
Shunsuke, Chikuma, Jeffrey A, Bluestone
openaire   +2 more sources

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

Science, 1995
P. Waterhouse, J. Penninger, E. Timms, A. Wakeham, A. Shahinian, Kelvin P. Lee, C. Thompson, H. Griesser, T. Mak   +8 more
semanticscholar   +1 more source

Anti-CTLA-4 Ab

2016
Ipilimumab (MDX-010, BMS-734016) is a fully human monoclonal immunoglobulin (IgG1) specific for human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD152), which is expressed on a subset of activated T cells as a negative regulator of T-cell activation.
openaire   +1 more source

Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop

Cell, 2021
Francesco Marangoni, Martin Thelen, Vinidhra Mani   +2 more
exaly